The phase 3 EXPEDITION3 trial has been abandoned, as Solanezumab failed to slow cognitive decline in tests on around 2,000 patients with Alzheimer’s Disease.
Several other amyloid-clearance drugs are going through trials apparently.
Walsh, F. (2016). Hopes for new Alzheimer’s drug dashed. London: BBC Health News, November 23rd 2016.
Earlier hopes (background):
Siemers, ER. Sundell, KL. [and] Carlson, C. [et al] (2016). Phase 3 solanezumab trials: secondary outcomes in mild Alzheimer’s disease patients. Alzheimer’s and Dementia. 2016 Feb;12(2):110-20.